Day: August 20, 2025

MEfBRVO: Eylea was compared to a control group in a Phase 3 studies in 181 patients with MEfBRVO. After 6 months, 98% of patients treated with Eylea maintained their eye vision, 53% of patients saw 15 or more letters on an eye chart compared to before treatment, and on average people saw 17 or more letters.